Is neglect of self-clearance biasing TB vaccine impact estimates?
exploring the inclusion of self-clearance in models of tuberculosis affects the estimates of vaccine impact in China and India
Epidemiological impact
Bridging the gap: evaluating high TB burden country data needs to support the potential introduction of TB vaccines for adolescents and adults: a workshop report
A workshop to asked high TB burden country experts about what epidemiological, impact, feasibility and acceptability data they anticipated they would need to guide TB vaccine introduction.
Estimating the potential public health value of BCG revaccination
Using previously calibrated models for India and South Africa, we simulated BCG revaccination assuming 45% prevention-of-infection efficacy, and we evaluated scenarios varying additional prevention-of-disease efficacy between +50% (reducing risk) and −50% (increasing risk).
Meeting the 2030 End TB goals in the wake of COVID-19: a modelling study of countries in the USAID TB portfolio.
From 2023 onwards we modelled a combination of interventions acting at different stages of the care cascade, including improved diagnostics; reducing the patient care seeking delay; and the rollout of a disease-preventing vaccine from 2025 onwards.
Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine
Using mathematical models, we seek to estimate the potential impact of a post-exposure TB vaccine, having 50% efficacy in reducing active disease, on global rifampicin-resistant (RR-) TB burden.
Acceptability and effect on public and cost-effectiveness impact
Understanding the acceptability of new TB vaccines, and their impact on health, cost-effectiveness, and budget, by socio-economic and risk group, in likely early adopter and other archetype countries.
Modelling the health and economic impacts of M72/AS01E vaccination and BCG-revaccination: estimates for South Africa
we used a mathematical model to estimate the health impact and cost-effectiveness of M72/AS01E and BCG-revaccination in South Africa under a range of vaccine characteristics and delivery assumptions
The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study
We estimated the impact of novel tuberculosis vaccines in low-income and middle-income countries (LMICs) in several delivery scenarios.
The potential impact of novel tuberculosis vaccines on health equity and financial protection in low-income and middle-income countries
We assessed the potential financial risk protection from introducing novel TB vaccines, and how health and economic benefits would be distributed across income quintiles.